Antiviral Drug · aiwiki.page

An antiviral drug is a medicine used to treat or prevent infection by a virus. Antivirals interfere with processes required for viral infection and reproduction, such as entry into cells, copying of genetic material, or processing of viral proteins. Their development depends on identifying targets that can be inhibited without unacceptable damage to the host’s cells, whose machinery viruses exploit. Antiviral medicines differ from antibacterial drugs and complement, rather than replace, vaccination. (ncbi.nlm.nih.gov)

Antivirals have transformed the management of several major infectious diseases. Combination antiretroviral therapy suppresses HIV replication, direct-acting antivirals can cure most hepatitis C infections, and other agents treat infections caused by herpesviruses, influenza viruses, and SARS-CoV-2. Their effects range from shortening acute illness to controlling persistent infection; suppression of viral replication does not necessarily eliminate the virus from the body. (pubweb-prod.niaid.nih.gov)

The subject encompasses drug mechanisms, disease-specific classes, pharmacological properties, clinical evaluation, and preventive uses. Major considerations include adverse effects and drug interactions, the evolution of antiviral resistance, and unequal access to diagnosis and medicines. Research also addresses new viral targets and treatments for viruses with pandemic potential. (accessdata.fda.gov)

Definition, Scope, and Biological Basis

An antiviral drug is a medicine that inhibits viral infection or replication within a host, either by interfering with the virus itself or by modifying host functions required for infection. Antiviral activity is distinct from symptom relief: a fever-reducing medicine may improve comfort without inhibiting viral reproduction. Antibacterial medicines act against bacteria rather than viruses; surface disinfectants inactivate infectious particles outside the body rather than treat intracellular infection. A vaccine induces an immune response against a pathogen, whereas an antiviral acts pharmacologically during its administration. This distinction is not simply treatment versus prevention, because antiviral drugs can also prevent infection in defined circumstances. (ncbi.nlm.nih.gov)

The biological difficulty of antiviral therapy follows from viruses being obligate intracellular parasites: they reproduce only within living cells. A viral genome supplies instructions for producing new infectious particles, but the host provides resources such as energy, molecular building blocks, and the machinery for protein synthesis. All viruses depend on host ribosomes; some additionally use host enzymes for copying or transcribing their genetic material. Consequently, a substance that stops viral replication by shutting down an essential cellular process may also injure uninfected tissue. Unlike antibacterial treatment directed at bacterial ribosomes, antiviral treatment cannot exploit a separate viral ribosome, because none exists. (ncbi.nlm.nih.gov)

Selective toxicity therefore depends on identifying a sufficiently distinctive viral function or a difference between infected and uninfected cells. Direct-acting antivirals target viral components, including enzymes involved in genome replication or protein processing. Acyclovir illustrates an additional route to selectivity: its initial activation depends on a thymidine kinase encoded by herpes simplex or varicella-zoster virus, and its active form inhibits viral DNA polymerase. Host-directed agents instead target cellular factors that viruses need. Maraviroc, for example, binds the host-cell receptor CCR5 and prevents entry by HIV-1 variants that use that receptor. Thus, “antiviral” describes the effect on infection, not necessarily a molecular target belonging to the virus. (ncbi.nlm.nih.gov)

Antiviral immunotherapies occupy an overlapping part of this terminology. Therapeutic interferons act through host-cell signaling rather than by binding a viral enzyme; interferon alfa induces antiviral effector proteins, including 2′,5′-oligoadenylate synthetase. Neutralizing monoclonal antibodies provide preformed immune proteins that recognize viral structures and can prevent attachment or membrane fusion. They are therefore antiviral biologics and forms of passive immunotherapy, although clinical discussions often distinguish them from small-molecule antiviral drugs. These categories describe different attributes: an antibody can be an immunotherapy by treatment type while acting directly against a viral surface protein. An immune-modifying treatment that only reduces inflammation, by contrast, is not necessarily antiviral. (accessdata.fda.gov)

An agent’s antiviral spectrum is the range of viruses or viral variants susceptible to it, not a general ability to treat every viral disease. Susceptibility depends on the presence and accessibility of its target, drug activation, and viral genetic variation. Maraviroc’s restriction to CCR5-using HIV-1 illustrates how spectrum can differ even within one viral species. Inhibiting active replication must also be distinguished from eliminating persistent infection: acyclovir and related herpes medicines control replicating virus but do not eradicate latent viral genomes, so recurrence remains possible after treatment ends. Conversely, persistence does not invariably prevent cure; effective direct-acting regimens can cure hepatitis C. Whether antiviral treatment suppresses or clears infection therefore depends on both drug action and the biological form in which the virus persists. (ncbi.nlm.nih.gov)

Historical Development

Early antiviral chemotherapy developed around nucleoside analogues, compounds resembling the building blocks of nucleic acids. In 1962, ophthalmologist Herbert E. Kaufman reported treating herpes simplex keratitis with idoxuridine, a thymidine analogue. Its clinical usefulness was principally topical: interference with host-cell as well as viral DNA synthesis made systemic administration too toxic. Vidarabine, an adenine analogue, subsequently extended treatment to severe systemic herpesvirus disease. A placebo-controlled study published in 1977 by Richard J. Whitley and colleagues demonstrated benefit in biopsy-proved herpes simplex encephalitis. These agents established that viral infections could respond to chemotherapy, but also exposed the limitations of compounds insufficiently selective for infected cells. (pubmed.ncbi.nlm.nih.gov)

The discovery of acyclovir at Burroughs Wellcome in 1974 provided a more selective approach; clinical trials began in 1977, and a topical formulation became available in 1982. In a 1977 experimental paper, Gertrude B. Elion, Phillip A. Furman, James A. Fyfe, and colleagues explained its selectivity. Herpesvirus thymidine kinase initiates conversion of the drug into phosphorylated derivatives, whereas activation occurs only to a limited extent in uninfected cells. The resulting triphosphate also preferentially inhibits viral DNA polymerase. In their experimental systems, it inhibited the viral enzyme 10–30 times more effectively than the cellular enzyme. This combination of selective activation and preferential targeting distinguished acyclovir from earlier, more broadly cytotoxic analogues. (pubmed.ncbi.nlm.nih.gov)

The emergence of HIV/AIDS accelerated development of drugs directed at additional viral enzymes. Zidovudine, also called azidothymidine or AZT, had originally been synthesized in 1964 as a potential anticancer compound; in March 1987 it became the first HIV medicine approved by the United States Food and Drug Administration (FDA). It inhibited reverse transcriptase, the enzyme that produces DNA from the viral RNA template. Early treatment relied on one or two nucleoside reverse-transcriptase inhibitors, but incomplete suppression and drug resistance limited their durability. Saquinavir became the first FDA-approved HIV protease inhibitor in December 1995. By 1996, research demonstrated that triple-drug treatment, commonly combining two nucleoside inhibitors with a protease inhibitor, could suppress replication much more durably while raising the barrier to resistance. The historical transition was therefore from sequential use of individual agents to simultaneous inhibition of complementary viral targets. (pubweb-prod.niaid.nih.gov)

Treatment of hepatitis C subsequently shifted from interferon-based regimens toward oral direct-acting combinations. The first FDA-approved direct-acting agents, boceprevir and telaprevir in 2011, inhibited the viral NS3/4A protease but still required pegylated interferon and ribavirin. Sofosbuvir, a nucleotide analogue targeting NS5B polymerase, received FDA approval on December 6, 2013. Approval of ledipasvir–sofosbuvir on October 10, 2014 introduced a single-tablet combination targeting NS5A and NS5B that did not require interferon or ribavirin for its initial adult genotype-1 indication. These milestones marked a move toward finite, all-oral courses capable of achieving sustained virological clearance rather than indefinite suppression. (accessdata.fda.gov)

During the COVID-19 pandemic, antiviral development included both redeployment of existing investigational compounds and development of new targeted agents. Remdesivir received an FDA emergency use authorization on May 1, 2020, followed on October 22, 2020 by approval for specified hospitalized patients—the first FDA approval of a COVID-19 treatment. On December 22, 2021, the FDA authorized oral nirmatrelvir–ritonavir for high-risk patients with mild-to-moderate disease. Nirmatrelvir inhibited a SARS-CoV-2 protease, while ritonavir slowed its breakdown rather than serving as the principal coronavirus-directed component. The authorization was supported by the randomized EPIC-HR trial in unvaccinated, high-risk, nonhospitalized adults, illustrating the importance of distinguishing emergency authorization from full approval and interpreting milestones within their studied populations. (fda.gov)

Molecular Targets and Mechanisms of Action

Attachment and fusion inhibitors prevent infection before the viral genome reaches its intracellular replication site. In HIV infection, the envelope protein gp120 engages cellular CD4 and a co-receptor before gp41 mediates fusion with the cell membrane. These interactions provide distinct targets: temsavir, the active form of fostemsavir, binds gp120 and inhibits attachment to CD4; maraviroc targets the host co-receptor CCR5, blocking entry by CCR5-using virus. Enfuvirtide binds the HR1 region of gp41 and prevents the conformational changes required for membrane fusion. Thus, entry inhibition can target either a viral surface protein or a cellular receptor, rather than an intracellular enzyme. (dailymed.nlm.nih.gov)

Nucleoside and nucleotide analogues interfere with viral nucleic-acid synthesis after intracellular activation. Acyclovir illustrates selective activation: herpesvirus thymidine kinase produces its monophosphate, and cellular enzymes subsequently generate acyclovir triphosphate. This metabolite competes with the natural substrate at viral DNA polymerase and terminates elongation after incorporation because it lacks the $3′$ -hydroxyl group needed for the next phosphodiester bond. Tenofovir, a nucleotide analogue delivered through prodrugs, undergoes cellular phosphorylation to tenofovir diphosphate, which inhibits HIV reverse transcriptase and hepatitis B polymerase through substrate competition and DNA-chain termination. The active metabolite’s name therefore need not contain “triphosphate” for it to act as a nucleotide substrate analogue. (dailymed.nlm.nih.gov)

Retroviral replication presents two sequential enzymatic targets: conversion of viral RNA into DNA, followed by insertion of that DNA into the host genome. Nucleoside reverse-transcriptase inhibitors interrupt the first process through incorporation into the growing DNA chain. Non-nucleoside inhibitors such as efavirenz inhibit the same reverse transcriptase without acting as incorporable nucleotide substrates; efavirenz’s activity is predominantly noncompetitive. Integrase strand-transfer inhibitors act downstream: dolutegravir binds the integrase active site and blocks the joining of viral DNA to cellular DNA. Blocking this integration step prevents establishment of newly integrated viral genomes; it does not excise genomes already integrated into cellular chromosomes. (hivinfo.nih.gov)

Viral proteases process large polyprotein precursors into functional components. HIV protease inhibitors such as darunavir prevent cleavage needed for production of mature infectious particles. In coronaviruses, proteolysis also supplies proteins required for replication: nirmatrelvir inhibits the SARS-CoV-2 main protease, also called $M^{pro}$ , 3CL protease, or nsp5, preventing processing of the pp1a and pp1ab polyproteins. Protease inhibition therefore does not identify one universal stage of action: depending on the virus, it can prevent particle maturation or production of the replication machinery itself. (hivinfo.nih.gov)

Structural assembly and genome packaging are additional targets. Lenacapavir binds interfaces between HIV capsid protein p24 subunits and disrupts several capsid-dependent processes, including nuclear uptake of viral DNA, particle assembly, and formation of correctly shaped capsid cores. Its action is consequently not confined to a single late replication step. Letermovir instead inhibits the cytomegalovirus DNA terminase complex, comprising pUL51, pUL56, and pUL89. This complex processes and packages viral DNA; inhibiting it interrupts production of genome-containing particles without directly inhibiting DNA polymerase. (dailymed.nlm.nih.gov)

In influenza, release and transcription are separate pharmacological targets. Oseltamivir’s active metabolite inhibits neuraminidase, impairing release of newly formed viral particles and their subsequent spread. Baloxavir marboxil is converted to baloxavir, which inhibits the cap-dependent endonuclease within the polymerase acidic protein. This enzyme participates in “cap-snatching,” the cleavage of capped host RNA to obtain primers for viral messenger-RNA synthesis. Baloxavir therefore interrupts viral transcription inside infected cells, whereas neuraminidase inhibitors act principally at the release stage. (dailymed.nlm.nih.gov)

Drugs for Herpesvirus Infections

For herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), acyclovir, valacyclovir, and famciclovir are principal systemic drugs. Valacyclovir is the L-valyl ester prodrug of acyclovir: conversion after absorption releases acyclovir, while improved oral absorption permits less frequent administration. Famciclovir is converted to penciclovir, a different active compound. In infected cells, viral thymidine kinase initiates phosphorylation of acyclovir or penciclovir; cellular enzymes produce the active triphosphates, which inhibit viral DNA polymerase. Acyclovir also terminates elongation of viral DNA. Dependence on viral activation contributes to selective activity in infected cells. (cdc.gov)

HSV treatment distinguishes finite courses for active episodes from continuing suppression of recurrences. Oral therapy shortens symptomatic genital episodes, whereas intravenous acyclovir is used for severe disseminated infection and central nervous system complications, including encephalitis. The CDC’s 2021 sexually transmitted infection guidelines report that daily suppressive therapy reduces genital herpes recurrences by 70–80% among people with frequent recurrences. Suppression reduces episodes and viral shedding during treatment, but does not eradicate latent infection or permanently alter recurrence risk after discontinuation. Thus, clinical control is distinct from elimination of the viral genome. (cdc.gov)

Varicella-zoster virus (VZV), the cause of chickenpox and herpes zoster, is also susceptible to acyclovir, valacyclovir, and famciclovir. For localized zoster, these agents accelerate lesion resolution, reduce formation of new lesions and viral shedding, and lessen acute pain; treatment has greatest effectiveness when begun within 72 hours of symptom onset. Disease extent and immune status affect the route of administration: NIH guidance for people with HIV distinguishes oral treatment of localized dermatomal zoster from intravenous acyclovir for extensive cutaneous disease or suspected visceral or central nervous system involvement. These uses treat productive infection rather than remove the latent VZV genomes responsible for later reactivation. (cdc.gov)

Cytomegalovirus (CMV) requires a different therapeutic emphasis. Ganciclovir and its orally absorbed prodrug valganciclovir are major agents for active CMV disease, including retinitis in people with advanced HIV. Ganciclovir activation begins principally through the CMV UL97 protein kinase rather than HSV thymidine kinase; subsequent cellular phosphorylation produces a triphosphate that inhibits viral DNA synthesis. CMV retinitis treatment separates an initial induction phase, generally lasting at least 14–21 days, from maintenance treatment when continuing suppression is necessary. Ganciclovir-associated cytopenias can limit therapy. (ncbi.nlm.nih.gov)

Foscarnet provides an alternative when ganciclovir resistance or toxicity complicates CMV treatment. This pyrophosphate analogue directly inhibits viral DNA polymerase without requiring phosphorylation by a viral kinase. Consequently, it can also retain activity against HSV strains whose defective thymidine kinase prevents acyclovir activation. Cidofovir is another alternative polymerase inhibitor. Neither drug is pharmacologically interchangeable with oral HSV treatments: intravenous administration and substantial renal toxicity constrain their use, particularly for prolonged CMV therapy. (ncbi.nlm.nih.gov)

Prevention in immunocompromised populations is a separate indication from treatment of established disease. Valganciclovir is used for CMV prophylaxis in specified organ-transplant populations. Letermovir instead targets the CMV terminase complex involved in viral DNA processing and packaging and is used for prophylaxis in defined transplant settings. In Francisco Marty and colleagues’ 2017 randomized trial among CMV-seropositive allogeneic hematopoietic-cell transplant recipients, the week-24 primary endpoint—clinically significant CMV infection or an imputed endpoint event—occurred in 37.5% of letermovir recipients versus 60.6% of placebo recipients among participants without detectable CMV DNA at randomization. This preventive application differs from treating CMV retinitis or other established end-organ disease. (dailymed.nlm.nih.gov)

Antiretroviral Drugs for HIV

Antiretrovirals are classified by the viral process or host interaction they inhibit. Reverse-transcriptase inhibitors prevent HIV from converting its RNA genome into DNA. Nucleoside and nucleotide reverse-transcriptase inhibitors, collectively abbreviated NRTIs, include lamivudine, emtricitabine, and tenofovir; their activated intracellular forms interrupt viral DNA synthesis. Non-nucleoside reverse-transcriptase inhibitors (NNRTIs), such as efavirenz and rilpivirine, inhibit reverse transcriptase through binding rather than incorporation into DNA. Integrase strand-transfer inhibitors (INSTIs), including dolutegravir, bictegravir, and raltegravir, prevent insertion of viral DNA into the host genome. Protease inhibitors, exemplified by darunavir, prevent cleavage of viral precursor proteins and thereby impair production of mature infectious particles. (clinicalinfo.hiv.gov)

Entry-related medicines comprise several mechanistically distinct classes. Maraviroc blocks the host CCR5 coreceptor; fostemsavir is an attachment inhibitor directed against the viral gp120-mediated attachment process; enfuvirtide inhibits fusion between the viral envelope and the cell membrane. Ibalizumab, a monoclonal antibody, acts after attachment through binding to CD4. These agents therefore interfere with different interactions rather than sharing one interchangeable “entry” target. The capsid inhibitor lenacapavir targets the protein shell surrounding the viral genetic material and disrupts functions at multiple stages of replication. Entry-related and capsid-targeting agents provide additional options when constructing regimens for viruses resistant to other classes. (hivinfo.nih.gov)

Combination antiretroviral therapy (ART) brings together active medicines with complementary inhibitory effects, producing deeper and more durable suppression than an inadequately active single agent and limiting opportunities for resistant variants to expand. A common three-drug architecture consists of an INSTI plus two NRTIs—for example, bictegravir with tenofovir alafenamide and emtricitabine. Some established regimens contain two drugs, such as dolutegravir and lamivudine, although their evidence and clinical indications are not identical to those of three-drug regimens. A regimen specifies the complete set of medicines used together; a fixed-dose combination describes a manufactured formulation containing specified amounts of multiple ingredients. One tablet can therefore contain a complete multidrug regimen, while another combination tablet supplies only part of a regimen requiring additional medicine. (clinicalinfo.hiv.gov)

Effective ART can maintain plasma HIV RNA below an assay’s detection limit while allowing recovery of CD4 T lymphocytes and immune function. Viral suppression and immune recovery are related but distinct outcomes: an undetectable viral load does not guarantee normalization of the CD4 count. NIH monitoring guidance describes an increase of approximately 50–150 CD4 cells per cubic millimetre during the first treatment year as an adequate immunological response for most people, with substantial individual variation. Suppression is not eradication. Long-lived infected cells in a latent HIV reservoir can retain viral genetic material without producing new virus; conventional antiretrovirals do not eliminate these cells, and viral replication can resume after treatment stops. (clinicalinfo.hiv.gov)

Oral and long-acting products are delivery approaches, not separate mechanistic classes. Many oral regimens are taken daily, either as individual products or combination tablets. Long-acting cabotegravir, an INSTI, and rilpivirine, an NNRTI, form an injectable two-drug regimen administered every month or every two months. In contrast, injectable lenacapavir is administered every six months for treatment but is combined with other active antiretrovirals: its prolonged action does not make it a complete treatment regimen by itself. These examples distinguish the dosing interval of an individual drug from the composition of the overall regimen. (hivinfo.nih.gov)

Long-acting delivery reduces dosing frequency by sustaining drug exposure, but it does not make different regimens clinically interchangeable. The evidence and indications for injectable cabotegravir–rilpivirine depend on factors including virological suppression, previous treatment failure, resistance, and relevant coinfections or interactions. Its use as replacement therapy in virologically suppressed adults entered United States regulatory practice in January 2021. Subsequent research has also examined populations with barriers to daily oral treatment. Thus, prolonged pharmacological activity describes how a formulation delivers medicine; treatment eligibility remains a separate question determined by the particular combination and the population studied. (clinicalinfo.hiv.gov)

Drugs for Viral Hepatitis

Chronic hepatitis B is treated principally with oral nucleoside or nucleotide analogues that suppress hepatitis B virus (HBV) DNA synthesis. Entecavir, a guanosine nucleoside analogue, is phosphorylated intracellularly to entecavir triphosphate. This metabolite inhibits three activities of the viral polymerase: initiation of DNA synthesis, reverse transcription of pregenomic RNA into negative-strand DNA, and positive-strand DNA synthesis. Tenofovir, a nucleotide analogue delivered as tenofovir disoproxil fumarate or tenofovir alafenamide, is converted to tenofovir diphosphate, which inhibits HBV polymerase and terminates the growing DNA chain. These agents reduce circulating HBV DNA, often below laboratory quantification limits; long-term suppression reduces progression to cirrhosis and lowers, but does not abolish, liver-cancer risk. Treatment commonly continues for years and may be lifelong. (dailymed.nlm.nih.gov)

Suppression does not mean elimination of HBV genetic material. Within infected hepatocyte nuclei, covalently closed circular DNA (cccDNA) persists as a template for viral transcription; HBV DNA integrated into the host genome can also produce hepatitis B surface antigen (HBsAg). Polymerase inhibitors do not directly remove either reservoir. Consequently, undetectable blood HBV DNA during treatment is distinct from functional cure: sustained HBsAg loss together with HBV DNA below the quantification limit after treatment ends, with or without development of antibodies against HBsAg. The 2022 AASLD–EASL treatment-endpoints conference specified assessment 24 weeks off treatment for this clinical-trial endpoint. Functional cure does not require disappearance of every viral DNA sequence, whereas sterilizing cure would require elimination of both cccDNA and integrated HBV DNA. (journal-of-hepatology.eu)

For hepatitis C, direct-acting antivirals are classified by three principal viral targets. NS3/4A protease inhibitors, including glecaprevir and voxilaprevir, block cleavage of the viral polyprotein into components needed for replication. NS5A inhibitors, including pibrentasvir, velpatasvir, and ledipasvir, target a nonenzymatic protein involved in viral RNA replication and particle assembly. NS5B polymerase inhibitors block RNA synthesis: sofosbuvir is a nucleotide analogue whose activated intracellular metabolite is incorporated into viral RNA and terminates chain elongation. Unlike HBV polymerase inhibition, effective HCV combination therapy can produce durable viral clearance after a finite treatment course. (fda.gov)

Representative oral combinations pair complementary targets: glecaprevir/pibrentasvir combines NS3/4A and NS5A inhibition, whereas sofosbuvir/velpatasvir combines NS5B and NS5A inhibition. Both have pangenotypic activity, covering the major HCV genotypes rather than requiring a separate drug combination for each genotype. Common simplified regimens for previously untreated adults without cirrhosis are eight weeks of glecaprevir/pibrentasvir or twelve weeks of sofosbuvir/velpatasvir. These durations are not universal: cirrhosis severity, previous treatment failure, and other clinical characteristics alter regimen selection, and protease-inhibitor-containing regimens are unsuitable in decompensated liver disease. (fda.gov)

The principal HCV cure endpoint is sustained virological response, conventionally SVR12: undetectable or unquantifiable HCV RNA at least twelve weeks after treatment completion. Effective direct-acting antiviral treatment cures more than 95% of treated people, although outcomes vary with the regimen and population. HCV antibodies generally remain detectable after cure, so antibody positivity does not establish continuing infection; recurrent infection is assessed using HCV RNA testing. SVR does not confer protective immunity, and subsequent exposure can cause reinfection. It also does not immediately reverse established cirrhosis: people with cirrhosis retain a residual risk of hepatocellular carcinoma after viral clearance. (who.int)

Drugs for Influenza and COVID-19

The influenza neuraminidase inhibitors oseltamivir, zanamivir, and peramivir are administered orally, by oral inhalation, and intravenously, respectively. They act against both influenza A and B by inhibiting the viral enzyme that cleaves terminal sialic acid residues, thereby restricting release of newly formed virus particles from infected cells. Baloxavir marboxil, given as a single oral dose, instead inhibits the viral cap-dependent endonuclease. This interrupts “cap-snatching,” in which the influenza polymerase complex obtains capped fragments of host-cell RNA to initiate viral messenger-RNA synthesis. Thus, neuraminidase inhibitors primarily interfere with viral release, whereas baloxavir interferes with transcription. (cdc.gov)

Amantadine and rimantadine, the older adamantane drugs, block the influenza A M2 ion channel and inhibit viral uncoating after entry into a cell; they do not provide useful activity against influenza B. Their historical importance predates neuraminidase inhibition: amantadine received United States approval for influenza treatment and prevention in 1976, and rimantadine in 1993. Widespread resistance among circulating seasonal influenza A viruses subsequently displaced these drugs from routine use; the US Centers for Disease Control and Prevention does not recommend them for seasonal influenza treatment or prevention. This is a limitation of viral susceptibility rather than of oral delivery or the underlying M2-targeting mechanism. (cdc.gov)

For uncomplicated influenza, evidence from randomized controlled trials chiefly establishes shorter illness when treatment begins within approximately 48 hours of symptom onset. Evidence in hospitalized patients is different: observational studies support benefit from oseltamivir, including when administration begins later than 48 hours, although these studies are more vulnerable to confounding than randomized comparisons. Findings from early-treatment outpatient trials therefore cannot simply be transferred to severe hospitalized disease, and reductions in symptom duration should not be treated as equivalent to demonstrated reductions in mortality. (cdc.gov)

Two major direct-acting treatments for COVID-19 target different SARS-CoV-2 replication proteins. Intravenous remdesivir is a nucleotide-analogue prodrug converted intracellularly to an active triphosphate, which the viral RNA-dependent RNA polymerase incorporates into newly synthesized RNA, causing delayed chain termination. Oral nirmatrelvir inhibits the viral main protease, also called Mpro or 3CLpro, preventing processing of viral polyproteins needed for replication. It is co-administered with ritonavir, whose role is pharmacokinetic boosting: inhibition of CYP3A-mediated metabolism increases nirmatrelvir exposure. Ritonavir does not itself inhibit the SARS-CoV-2 main protease; its enzyme-inhibiting activity also creates clinically important drug interactions. (accessdata.fda.gov)

COVID-19 trial results illustrate the importance of treatment timing and baseline risk. In PINETREE, published in 2022, a three-day remdesivir course begun within seven days of symptom onset in unvaccinated, higher-risk outpatients produced COVID-19-related hospitalization or all-cause death in 0.7% of recipients versus 5.3% with placebo—an absolute difference of 4.6 percentage points. In contrast, the 2024 EPIC-SR trial of nirmatrelvir–ritonavir enrolled vaccinated adults with risk factors and unvaccinated adults without such factors, within five days of symptom onset. Hospitalization or death occurred in 0.8% versus 1.6%, a difference that was not statistically significant; symptom alleviation was not significantly accelerated. These differently constituted populations do not support a single, population-independent estimate of antiviral benefit. (nejm.org)

Antiviral treatment is distinct from controlling the host inflammatory injury associated with severe COVID-19. Corticosteroids such as dexamethasone suppress inflammation rather than directly inhibit SARS-CoV-2 replication; their established role is in severe or critical disease, not indiscriminate treatment of mild infection. Neither antiviral drugs nor anti-inflammatory treatment substitutes for vaccination against influenza or COVID-19, which establishes immune protection before a subsequent encounter with the virus. (who.int)

Pharmacokinetics, Formulations, and Safety

Pharmacokinetics describes drug absorption, distribution, metabolism, and elimination; antiviral activity may additionally require conversion into an active compound inside infected cells. Oral acyclovir has an average bioavailability of only 10–20%. Valacyclovir, its L-valyl ester prodrug, improves delivery: after intestinal absorption, first-pass intestinal and hepatic metabolism converts it almost completely to acyclovir and L-valine. A study in 12 healthy volunteers found acyclovir bioavailability of 54.5% after oral valacyclovir. This chemical modification increases systemic exposure without changing the ultimate active antiviral. Within herpesvirus-infected cells, viral thymidine kinase initiates acyclovir phosphorylation, and cellular enzymes complete its conversion to acyclovir triphosphate. Prodrug conversion and intracellular activation are therefore distinct processes. (dailymed.awsprod.nlm.nih.gov)

Distribution and elimination determine whether adequate concentrations reach infected tissues and how long exposure persists. After intravenous acyclovir, cerebrospinal-fluid concentrations are approximately 50% of plasma concentrations; 62–91% of the administered dose is eliminated unchanged through the kidneys. Its plasma half-life consequently depends strongly on renal function. Plasma exposure alone also does not describe intracellular activation: delivery of acyclovir to a tissue must be followed by phosphorylation within cells to produce its active triphosphate. (dailymed.nlm.nih.gov)

Formulations produce different exposure patterns and delivery requirements. Topical acyclovir cream provides local treatment with minimal systemic absorption, whereas oral formulations deliver drug systemically through gastrointestinal absorption. Intravenous acyclovir bypasses that absorption step but requires venous access and controlled infusion. Inhaled zanamivir deposits drug in the respiratory tract through a dry-powder device, making delivery dependent on inhalation technique; bronchospasm is a formulation-specific safety concern. (dailymed.nlm.nih.gov) Long-acting intramuscular cabotegravir–rilpivirine, first approved in the United States in 2021, instead uses slowly absorbed injectable suspensions for monthly or every-two-month administration. Apparent terminal half-lives are 5.6–11.5 weeks for cabotegravir and 13–28 weeks for rilpivirine, largely reflecting slow release from injection sites. This permits extended dosing intervals but requires scheduled injections and leaves prolonged residual exposure after discontinuation. (dailymed.nlm.nih.gov)

Toxicity is drug-specific rather than a uniform property of antivirals. Intravenous acyclovir can precipitate as crystals in renal tubules, causing renal injury; its labeling therefore specifies controlled infusion and adequate hydration. Reduced renal clearance can also increase exposure and neurological toxicity. (dailymed.nlm.nih.gov) Ganciclovir has a different prominent toxicity profile: neutropenia, anemia, thrombocytopenia, and occasionally pancytopenia. Its substantial renal elimination connects kidney impairment with greater exposure, while blood-cell counts and renal-function measurements address different safety risks. Hepatic impairment matters for other agents: nirmatrelvir–ritonavir labeling does not recommend use in severe hepatic impairment. Thus, renal and hepatic function cannot be treated as interchangeable measures of antiviral tolerability. (dailymed.nlm.nih.gov)

Enzyme-mediated interactions can deliberately improve exposure or unintentionally produce toxicity. Ritonavir strongly inhibits CYP3A, an enzyme system involved in drug metabolism. In nirmatrelvir–ritonavir, this inhibition reduces nirmatrelvir breakdown and raises its plasma concentrations; ritonavir does not inhibit the SARS-CoV-2 main protease at issue in that combination. The same mechanism can increase concentrations of concomitant CYP3A substrates, including certain antiarrhythmics and sedatives, with potentially severe consequences. Conversely, strong enzyme inducers can reduce antiviral exposure. Pharmacokinetic boosting therefore changes the interaction profile of the entire regimen, not merely the concentration of its antiviral component. (dailymed.nlm.nih.gov)

Evidence must also be established separately for pregnancy, childhood, older age, and immunocompromise. Pregnancy assessment includes fetal outcomes as well as maternal tolerability: international acyclovir and valacyclovir registries collected exposure data through April 1999, separately from ordinary adult trials. Pediatric studies address age-dependent exposure rather than assuming that proportional reductions in adult doses are equivalent; older adults may have reduced renal clearance. (dailymed.nlm.nih.gov) Immunocompromised populations likewise require indication- and formulation-specific evidence: the effectiveness of acyclovir cream has not been established in immunocompromised patients, despite its minimal systemic absorption. (dailymed.nlm.nih.gov)

Therapeutic and Preventive Uses and Clinical Evidence

Treatment of established infection and suppressive therapy differ principally in duration and purpose. Treatment of acute influenza aims to shorten illness and prevent complications during an episode of active infection. Suppressive therapy maintains control over a persistent infection: combination antiretroviral treatment for HIV continuously inhibits replication, reducing viral load and the risk of illness and death without eradicating infection. Suppression can also reduce recurrent disease. The CDC’s 2021 sexually transmitted infection guidelines report that suppressive treatment reduces genital herpes recurrence frequency by 70–80% in patients with frequent recurrences; episodic treatment instead targets individual outbreaks. These uses therefore require different measures of success and different periods of observation. (cdc.gov)

Pre-exposure prophylaxis (PrEP) administers antiviral medication to uninfected people before potential exposure, whereas post-exposure prophylaxis (PEP) begins after a possible exposure, before infection becomes established. HIV PrEP uses antiretroviral medication in people without HIV; diagnostic testing distinguishes this preventive use from treatment of existing infection. The CDC’s 2025 nonoccupational HIV PEP recommendations specify initiation as soon as possible, ideally within 24 hours and no later than 72 hours after exposure, followed by a 28-day course. Influenza PEP provides another documented example: a randomized Japanese household-contact trial published in 2020 found laboratory-confirmed clinical influenza in 1.9% of evaluable baloxavir recipients versus 13.6% of placebo recipients. This represented an absolute difference of 11.7 percentage points, not complete protection. (cdc.gov)

Clinical endpoints distinguish effects on infection from effects that patients directly experience. Symptom duration, recurrence frequency, hospitalization, and death measure illness burden; viral load measures the amount of virus or viral genetic material in a specimen. Such laboratory biomarkers can serve as surrogate endpoints, but their interpretation depends on validation for the particular infection and treatment context. The FDA recognizes HIV RNA reduction and sustained hepatitis C virological response as surrogate endpoints used in drug approval. For hepatitis C, sustained virological response 12 weeks after treatment ends, or SVR12, is considered virological cure; it is not a direct measurement of subsequent liver complications or survival. A trial showing faster viral clearance therefore does not automatically establish fewer hospitalizations or deaths. (fda.gov)

A randomized controlled trial compares outcomes between groups assigned to antiviral treatment and a comparator, often placebo. Random allocation helps separate treatment effects from differences in underlying risk. Timing is particularly important in acute infections: CDC reviews of influenza trials identify the greatest benefit when treatment begins within 48 hours of illness onset. Evidence from hospitalized patients includes observational studies suggesting benefit from later treatment, but this evidence differs methodologically from randomized trials of early treatment in uncomplicated outpatient illness. Results from one disease stage cannot simply be transferred to another. (pubmed.ncbi.nlm.nih.gov)

Prior immunity and the enrolled population also affect measured benefit. In the EPIC-HR trial, published in 2022, nirmatrelvir–ritonavir was studied in unvaccinated, high-risk adults with COVID-19 outside hospital. Its planned interim analysis among participants treated within three days of symptom onset found hospitalization or death by day 28 in 0.77% of treated participants versus 7.01% receiving placebo. By contrast, the EPIC-SR trial, published in 2024, enrolled vaccinated adults with risk factors and unvaccinated adults without those risk factors. Median time to sustained symptom alleviation was 12 versus 13 days, a difference that was not statistically significant. These trials addressed different populations and endpoints, rather than providing interchangeable estimates of effectiveness. (nejm.org)

Preventive antiviral use complements rather than replaces other infection-control measures. Influenza antivirals are not substitutes for vaccination; during institutional outbreaks, chemoprophylaxis may be used alongside vaccination and outbreak-control measures. HIV PrEP similarly operates within a prevention programme incorporating HIV testing, screening for other sexually transmitted infections, condoms, and safer injection practices. Its effectiveness depends on maintaining appropriate drug exposure, and it does not prevent other sexually transmitted infections. Testing before and during prophylaxis also distinguishes prevention from an unrecognized infection requiring a treatment regimen. (cdc.gov)

Antiviral Resistance

Antiviral resistance is a heritable reduction in a virus’s susceptibility to a drug; it is a property of the virus, not the patient’s body becoming accustomed to treatment. During replication, mutations generate genetic variants, some of which alter drug targets or other functions required for antiviral activity. Drug exposure then imposes natural selection: susceptible variants are inhibited more strongly, allowing resistant variants to increase in relative abundance. Resistance-associated variants can already be present before treatment or arise during continuing replication. Drug exposure therefore selects resistance rather than directing the virus to produce a particular mutation. (hivinfo.nih.gov)

Acquired resistance develops within an infected individual, generally during treatment, whereas transmitted resistance occurs when infection is established by an already resistant virus. Consequently, previous antiviral use is not a prerequisite for resistant infection. Cross-resistance means that a change reducing susceptibility to one drug also reduces susceptibility to another, often because the drugs interact with the same target. In HIV, resistance to emtricitabine can confer resistance to lamivudine. In influenza, the H275Y substitution—replacement of histidine by tyrosine at position 275 of the neuraminidase protein in susceptible A(H1N1) backgrounds—confers oseltamivir resistance and also reduces susceptibility to peramivir. Cross-resistance does not necessarily extend equally to every member of a class. (hivinfo.nih.gov)

The genetic barrier to resistance concerns the number and nature of genetic changes required for clinically important resistance. A low-barrier drug may lose substantial activity after relatively few changes; higher-barrier drugs require less readily achieved evolutionary pathways. HIV integrase inhibitors illustrate this distinction: raltegravir and elvitegravir have lower resistance barriers than dolutegravir and bictegravir. Nevertheless, a high barrier does not make resistance impossible. Incomplete viral suppression allows continuing replication, while inadequate exposure caused by missed doses, impaired absorption, drug interactions, or treatment interruptions can create conditions favouring selection. Different drug half-lives can also leave an interrupted combination with uneven residual activity. (clinicalinfo.hiv.gov)

Resistance investigations provide different kinds of evidence. Genotypic testing uses sequencing of relevant viral genes to identify substitutions associated with resistance. Phenotypic testing measures viral replication across drug concentrations, commonly reporting the change in the concentration required for 50% inhibition relative to a reference virus. Viral-load monitoring instead measures the amount of viral nucleic acid: it can reveal inadequate suppression or rebound but does not identify the underlying mechanism. Tests also have detection limits. In HIV, resistant variants may become less abundant after selective drug pressure is removed, so a later genotype can miss previously selected resistance; historical results remain relevant even when those mutations are no longer detected. (clinicalinfo.hiv.gov)

Effective combination therapy limits resistance by suppressing replication with multiple active agents, reducing opportunities for variants resistant to an individual component to expand. Merely adding drugs is not equivalent to constructing an active combination: pre-existing resistance can leave a nominally multidrug regimen with too few effective components. Conversely, treatment failure does not prove resistance. Poor absorption, interrupted access, intolerance, or drug interactions may reduce exposure without demonstrable resistant virus. Clinical interpretation therefore integrates treatment history, exposure, serial viral-load measurements, and resistance results rather than treating any single finding as decisive. (clinicalinfo.hiv.gov)

At population level, resistance surveillance tracks susceptibility patterns and informs treatment policy. The World Health Organization’s 2024 HIV drug-resistance report documented viral suppression above 90% in populations receiving dolutegravir-containing treatment, while reporting dolutegravir resistance of 3.9–8.6% in surveyed groups not achieving suppression, reaching 19.6% in a highly treatment-experienced group with high viral loads at transition. These percentages describe selected unsuppressed groups, not all dolutegravir recipients. Influenza surveillance similarly combines genetic analysis and susceptibility testing to detect resistant circulating variants and their spread. (who.int)

Drug Discovery, Evaluation, and Research Challenges

Antiviral research and development begins by identifying a viral component or host process essential to infection and determining whether its inhibition can spare normal cellular functions. Biochemical screening tests compounds against isolated targets, such as a viral enzyme, whereas cell-based screening measures inhibition of infection or replication in living cells. These approaches provide complementary evidence: enzyme inhibition establishes activity against a proposed target, while cellular experiments test whether a compound reaches its site of action and remains active in a biological environment. Lead optimization modifies promising molecules to improve potency, selectivity, absorption, and metabolic stability. Preclinical assessment then examines exposure, toxicity, and, where suitable models exist, antiviral effects in animals. Dafydd Owen and colleagues’ 2021 report on PF-07321332, subsequently named nirmatrelvir, illustrates this progression through protease inhibition, cell-based antiviral testing, oral activity in mice, and exposure measurements in a phase 1 study. (fda.gov)

Laboratory potency alone does not establish therapeutic usefulness. Apparent inhibition of viral replication can result from damage to the host cells supporting it; antiviral assays therefore require parallel cytotoxicity measurements. One screening measure is the selectivity index, $SI=CC_{50}/EC_{50}$ , comparing the concentration causing 50% cellular cytotoxicity with that producing 50% antiviral effect. A favorable ratio remains insufficient if effective concentrations cannot be reached safely in infected tissues. The choice of cell model also matters. In 2020, Markus Hoffmann and colleagues showed that chloroquine inhibited SARS-CoV-2 infection in monkey-kidney-derived Vero cells but not in the human lung cell line Calu-3. Expression of the host protease TMPRSS2 made Vero-cell infection insensitive to chloroquine, demonstrating how different viral-entry pathways can change an assay’s result. (fda.gov)

Human clinical trials investigate questions that preclinical experiments cannot resolve. Phase 1 emphasizes tolerability, pharmacokinetics, and dose-related effects; phase 2 examines preliminary efficacy and dose selection in affected populations; phase 3 expands assessment of efficacy and safety, commonly through randomized controlled comparisons. In the United States, ordinary marketing approval requires substantial evidence of effectiveness and an acceptable safety profile for the proposed use, together with manufacturing-quality evidence. Emergency use authorization is a distinct legal pathway, not equivalent approval: under an applicable emergency declaration, the Food and Drug Administration may authorize a product when the totality of evidence supports a reasonable belief that it may be effective, its known and potential benefits outweigh its known and potential risks, and no adequate, approved, available alternative exists. Emergency authorization can therefore rest on less complete evidence than approval. (fda.gov)

Broader-spectrum research seeks targets sufficiently conserved across related viruses to make advance development possible before a particular outbreak. However, activity against several members of one family does not establish activity against unrelated viruses or clinical benefit against every tested pathogen. Pandemic-preparedness programmes have pursued this family-based approach: on May 18, 2022, the US National Institutes of Health announced approximately $577 million to establish nine Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern. Their remit included candidate drugs against coronaviruses and families containing pathogens such as Ebola, dengue, and enteroviruses. These awards supported discovery and development goals, rather than establishing universal antiviral treatments. (pubmed.ncbi.nlm.nih.gov)

Persistent obstacles include host-cell toxicity, differences in susceptibility among viral genotypes, and the emergence of resistance; development programmes consequently examine diverse clinical isolates, resistance selection, and cross-resistance alongside potency. Cure presents an additional problem when persistence does not depend on continuous production of drug-sensitive viral targets. In HIV infection, long-lived cells can retain latent viral genetic material despite effective suppression of replication. Conventional antiretroviral drugs do not eliminate these reservoirs, which can restart virus production after treatment stops. Reservoir-directed research therefore investigates mechanisms beyond replication inhibition, including elimination or durable silencing of infected cells. (fda.gov)

Access, Delivery, and Public Health

Antiviral access depends on a linked sequence of diagnosis, clinical assessment, medicine procurement, dispensing, and continued care. Laboratory capacity supports both identification of infection and treatment monitoring; supplying tablets alone does not provide these services. For HIV, WHO’s 2021 consolidated guidelines described differentiated delivery for people established on antiretroviral therapy, including less frequent clinic visits, multi-month dispensing, and community distribution. These arrangements reduce the frequency of medicine-collection visits while retaining clinical follow-up and viral-load monitoring. WHO’s service-delivery framework also treats adherence assessment and retention in care as distinct components of treatment provision, rather than assuming that a prescription ensures continuous use. (who.int)

Generic manufacture, licensing, and pooled purchasing address different barriers. Voluntary licences authorize manufacturers to use specified patented technologies within agreed territories; they do not themselves establish product quality or organize clinical services. On 20 January 2016, the Medicines Patent Pool announced non-exclusive, royalty-free daclatasvir sublicences with Cipla, Emcure, Hetero, and Natco covering 112 low- and middle-income countries. Separately, the World Health Organization prequalification programme assesses whether medicines meet international quality, safety, and efficacy standards, supporting international procurement. For HIV programmes, the Global Fund’s Pooled Procurement Mechanism aggregates orders to negotiate prices and delivery conditions. In August 2023, competitive tenders secured tenofovir disoproxil fumarate–lamivudine–dolutegravir for under US$45 per person annually, a 25% reduction. This was a medicine procurement price, not the total cost of testing, monitoring, staffing, and care. (medicinespatentpool.org)

Dated hepatitis data illustrate the difference between affordable products and accessible treatment. WHO’s April 2024 report estimated that, globally at the end of 2022, 13% of people with chronic hepatitis B had been diagnosed and approximately 3% had received antiviral therapy; for hepatitis C, the corresponding figures were 36% and 20%. In the WHO Western Pacific Region, hepatitis B treatment coverage was only 23% even among people already diagnosed. Procurement also varied: only seven of 26 reporting countries obtained tenofovir at or below the US$2.40 monthly benchmark, and only four of 24 obtained a 12-week sofosbuvir–daclatasvir course at or below US$60. In the WHO African Region, only about one third of reporting countries provided hepatitis testing and treatment wholly or partly free in the public sector. These measures describe different gaps: undiagnosed infection, treatment linkage, purchasing prices, and patients’ financial exposure. (who.int)

Delivery constraints become especially important when treatment must begin promptly. US outpatient COVID-19 protocols specify initiation of nirmatrelvir–ritonavir within five days of symptom onset and remdesivir within seven days; outpatient remdesivir requires intravenous administration on three consecutive days. Consequently, timely assessment and dispensing—and, for infusion treatment, repeated access to facilities, staff, and equipment—are operational requirements, not incidental additions to medicine supply. Short initiation windows leave limited time to overcome delays between symptom recognition, clinical assessment, and obtaining treatment. Infusion-based delivery also creates transport and scheduling requirements absent from an entirely oral course. (cdc.gov)

Outbreak preparedness combines antiviral reserves with distribution arrangements and public-health surveillance. In the United States, neuraminidase inhibitors were released from the Strategic National Stockpile during the 2009 H1N1 influenza pandemic. CDC surveillance tests seasonal and novel influenza viruses for reduced antiviral susceptibility, providing evidence that can inform guidance and preparedness decisions. Stockpile management therefore concerns both the availability of treatment courses and whether circulating viruses remain susceptible to the medicines held. These population-level functions—maintaining emergency supplies, organizing deployment, and monitoring susceptibility—are distinct from deciding whether a particular patient is eligible for a particular antiviral. (cdc.gov)

References

Chemotherapy of Viral Infections - Medical Microbiologyncbi.nlm.nih.gov
Treatment of Flucdc.gov
What’s the difference between products that disinfect, sanitize, and clean surfaces?epa.gov
Treating Influenza (Flu)cdc.gov
Cell Biology of Infection - Molecular Biology of the Cellncbi.nlm.nih.gov
Structure and Classification of Viruses - Medical Microbiologyncbi.nlm.nih.gov
Introduction to Pathogens - Molecular Biology of the Cellncbi.nlm.nih.gov
SELZENTRY (maraviroc) prescribing informationaccessdata.fda.gov
PEGASYS (peginterferon alfa-2a) prescribing informationaccessdata.fda.gov
Virus Entry and Its Inhibition by Antibodies: Studies to Aid the Development and Evaluation of Vaccines that Protect against Viral Infectious Diseasesfda.gov
Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19fda.gov
Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridinepubmed.ncbi.nlm.nih.gov
Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitispubmed.ncbi.nlm.nih.gov
History, pharmacokinetics, and pharmacology of acyclovirpubmed.ncbi.nlm.nih.gov
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guaninepubmed.ncbi.nlm.nih.gov
HIV Drug-resistant Strains as Epidemiologic Sentinelswwwnc.cdc.gov
Center for Drug Evaluation and Research Summary Review: Glecaprevir/Pibrentasviraccessdata.fda.gov
Harvoni and Sovaldi Postmarketing Safety Reviewfda.gov
U.S. Food and Drug Administration Approves Gilead’s Harvonigilead.com
FDA Approves First Treatment for COVID-19fda.gov
Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19fda.gov
DailyMed — RUKOBIA: fostemsavir tromethaminedailymed.nlm.nih.gov
DailyMed — FUZEON: enfuvirtidedailymed.nlm.nih.gov
DailyMed — ACYCLOVIR capsuledailymed.nlm.nih.gov
DailyMed — VIREAD: tenofovir disoproxil fumaratedailymed.nlm.nih.gov
The HIV Life Cycle — NIHhivinfo.nih.gov
DailyMed — EFAVIRENZ tablet, film coateddailymed.nlm.nih.gov
TIVICAY: prescribing informationdailymed.nlm.nih.gov
PAXLOVID: prescribing informationdailymed.nlm.nih.gov
SUNLENCA: prescribing informationdailymed.nlm.nih.gov
DailyMed — PREVYMIS: letermovirdailymed.nlm.nih.gov
DailyMed — TAMIFLU: oseltamivir phosphatedailymed.nlm.nih.gov
DailyMed - FAMCICLOVIR tablet, film coateddailymed.nlm.nih.gov
DailyMed - VALGANCICLOVIR- valganciclovir hydrochloride tablet, film coateddailymed.nlm.nih.gov
PREVYMIS (letermovir): Prescribing Informationaccessdata.fda.gov
FDA-Approved HIV Medicineshivinfo.nih.gov
Starting an HIV Treatment Regimenhivinfo.nih.gov
What is a Latent HIV Reservoir?hivinfo.nih.gov
Long-Acting HIV Medicinehivinfo.nih.gov
DailyMed — Entecavir tablet, film coateddailymed.nlm.nih.gov
DailyMed — Viread prescribing informationdailymed.nlm.nih.gov
Hepatitis Bwho.int
Pathway to global elimination of hepatitis B: HBV curedoi.org
Clinical and CDTL Reviewfda.gov
DailyMed — Epclusa prescribing informationdailymed.nlm.nih.gov
Hepatitis Cwho.int
Mavyret fixed-dose combination reviewfda.gov
Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnosticsncbi.nlm.nih.gov
Monitoring Persons Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Antiviral Therapyhcvguidelines.org
Influenza Antiviral Medications: Summary for Clinicianscdc.gov
Neuraminidase Inhibitors for Treatment of Influenza A and B Infectionscdc.gov
What are the mechanisms of action of the antivirals?ncbi.nlm.nih.gov
VEKLURY prescribing informationaccessdata.fda.gov
March 16, 2023 Meeting of the Antimicrobial Drugs Advisory Committee Meetingfda.gov
Coronavirus disease (COVID-19): Corticosteroids, including dexamethasonewho.int
Treating Flu with Antiviral Drugscdc.gov
Coronavirus disease (COVID-19)who.int
DailyMed — Acyclovirdailymed.awsprod.nlm.nih.gov
DailyMed — Valtrex (valacyclovir hydrochloride) tabletsdailymed.nlm.nih.gov
DailyMed — Acyclovir sodium injectiondailymed.nlm.nih.gov
DailyMed — Acyclovir creamdailymed.nlm.nih.gov
DailyMed — Relenza (zanamivir) powderdailymed.nlm.nih.gov
DailyMed — Cabenuva (cabotegravir and rilpivirine)dailymed.nlm.nih.gov
DailyMed — Acyclovir injectiondailymed.nlm.nih.gov
DailyMed — Ganciclovir injectiondailymed.nlm.nih.gov
DailyMed — Paxlovid (nirmatrelvir and ritonavir)dailymed.nlm.nih.gov
DailyMed — Ritonavir tabletsdailymed.nlm.nih.gov
Herpes - STI Treatment Guidelinescdc.gov
Clinical Guidance for PrEPcdc.gov
Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV — CDC Recommendations, United States, 2025cdc.gov
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contactspubmed.ncbi.nlm.nih.gov
Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensurefda.gov
CDTL Mavyretfda.gov
HIV Drug Resistancehivinfo.nih.gov
Influenza Antiviral Drug Resistancecdc.gov
HIV drug resistance – brief report 2024who.int
Division of Antivirals (DAV) Information for Pre-IND Submissionsfda.gov
The Drug Development Processfda.gov
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19pubmed.ncbi.nlm.nih.gov
Antiviral Product Development — Conducting and Submitting Virology Studies to the Agencyfda.gov
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2nature.com
Drug Development and Review Definitionsfda.gov
New Drug and Antibiotic Regulations: part 3fda.gov
Understanding FDA Terms for Possible New Therapies to Prevent and Treat Diseasesfda.gov
Emergency Use Authorization of Medical Products and Related Authoritiesfda.gov
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approachwho.int
The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvirmedicinespatentpool.org
Prequalification of health productswho.int
Global Fund Agreements Substantially Reduce the Price of First-line HIV Treatment to Below US$45 a Yeartheglobalfund.org
WHO sounds alarm on viral hepatitis infections claiming 3500 lives each daywho.int
COVID-19 Treatment Clinical Care for Outpatientscdc.gov
Types of COVID-19 Treatmentcdc.gov